法国HIV医院数据库中联合抗逆转录病毒治疗时代进行性多灶性白质脑病的风险
在法国HIV医院数据库(FHDH-ANRS CO4)中前瞻性随访1997至2011年无PML史的HIV-1感染者,采用Cox模型计算调整风险比,发现近期启动cART、注射吸毒和HCV血清阳性与PML风险升高相关,撒哈拉以南非洲起源无保护作用。
要点
- 近期启动cART(<6个月)与PML发病相关,调整HR为4.91(95%CI 2.42-9.95)。
- 注射吸毒者较男男性行为者PML风险更高,男性HR 1.80(95%CI 1.32-2.45),女性HR 1.68(95%CI 1.13-2.48)。
- 排除注射吸毒者后,HCV血清阳性与PML风险升高相关,HR为1.40(95%CI 1.02-1.93)。
核心结论
- 近期启动cART与PML风险升高相关,注射吸毒和HCV血清阳性亦相关,撒哈拉以南非洲起源无保护作用。
研究设计与样本
- 前瞻性队列研究,纳入法国HIV医院数据库(FHDH-ANRS CO4)中1997至2011年随访的≥15岁无PML史HIV-1感染者,采用Cox模型计算调整HR。
主要发现
- 555例发生PML,其中57例在cART启动后前6个月内发生。
- PML发病率从1997-2000年的1.15/1000人年(95%CI 0.98-1.31)降至2009-2011年的0.49/1000人年(95%CI 0.37-0.61)。
- 撒哈拉以南非洲起源无明确影响,HR为0.80(95%CI 0.58-1.11)。
- 与男男性行为者相比,男性注射吸毒者HR为1.80(95%CI 1.32-2.45),女性注射吸毒者HR为1.68(95%CI 1.13-2.48)。
- 排除注射吸毒者后,HCV血清阳性与风险升高相关,HR为1.40(95%CI 1.02-1.93);与未启动cART相比,启动<6个月与PML发病相关,HR为4.91(95%CI 2.42-9.95)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Risk factors for progressive multifocal leukoencephalopathy (PML) in individuals with human immunodeficiency virus (HIV) infection are poorly documented in the era of combination antiretroviral therapy (cART). METHODS: We studied HIV-1-infected individuals aged ≥15 years who had no history of PML and were prospectively followed up between 1997 and 2011 in the French Hospital Database on HIV (FHDH-ANRS CO4) cohort. Cox models were used to calculate adjusted hazard ratios (HRs), focusing on sub-Saharan origin, suggested to be protective, and recent cART initiation, potentially associated with an increased risk of PML. RESULTS: PML developed in 555 individuals, in 57 during the first 6 months of cART. From 1997-2000 to 2009-2011, the incidence fell from 1.15 (95% confidence interval [CI], .98-1.31) to 0.49 (.37-.61) per 1000 person-years. Sub-Saharan African origin had no clear influence (HR, 0.80; 95% CI, .58-1.11). Compared with men who have sex with men, injection drug users (IDUs) were at higher risk (HR, 1.80 [95% CI, 1.32-2.45] for male and 1.68 [1.13-2.48] for female IDUs). When IDUs were excluded, hepatitis C virus seropositivity was associated with an increased risk (HR, 1.40; 95% CI, 1.02-1.93). Compared with no cART initiation, initiation <6 months previously was associated with PML onset (HR, 4.91; 95% CI, 2.42-9.95). CONCLUSIONS: Recent cART initiation is associated with an increased risk of PML, as are injection drug use and hepatitis C virus seropositivity. Sub-Saharan African origin had no protective effect.
引用
- Melliez H, Mary-Krause M, Bocket L, et al. Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4). Clin Infect Dis. 2018. PMID: 29635465. doi:10.1093/cid/ciy074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。